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Abstract
Background: Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are increased in populations with immune dys-
function, including people living with HIV; however, there is little evidence for to what degree immunological and virological
factors differently affect NHL and HL risk.
Methods: Data from the Data Collection on Adverse events of Anti-HIV Drugs Study cohort were analyzed to identify indepen-
dent risk factors for NHL and HL using hazard ratios (HRs), focusing on current and cumulative area under the curve (AUC)
measures of immunological and virological status. Variables with different associations with NHL and HL were identified us-
ing marginal Cox models. All statistical tests were two-sided.
Results: Among 41 420 people followed for 337 020 person-years, 392 developed NHL (incidence rate ¼ 1.17/1000 person-years
of follow-up [PYFU], 95% confidence interval [CI] ¼ 1.06 to 1.30) and 149 developed HL (incidence rate ¼ 0.44/1000 PYFU, 95%
CI¼0.38 to 0.52). Higher risk of both NHL and HL was associated with lower current CD4 cell count (adjusted HR [aHR] of NHL
for CD4 <100 vs>599 cells/mm3 ¼ 8.08, 95% CI¼5.63 to 11.61; HL¼4.58, 95% CI¼2.22 to 9.45), whereas higher current HIV
viral load (aHR of NHL for HIV-VL >1000 vs<50 copies/mL ¼ 1.97, 95% CI¼1.50 to 2.59) and higher AUC of HIV-VL (aHR of NHL
for highest vs lowest quintile ¼ 2.91, 95% CI¼1.92 to 4.41) were associated with NHL only. Both current and AUC of HIV-VL
were factors that had different associations with NHL and HL, where the hazard ratio for NHL was progressively higher than
for HL with increasing HIV-VL category. Lower current CD4 cell count had a strong but similar association with both NHL
and HL.
Conclusions: CD4 depletion increased risk of both types of lymphomas while current and accumulated HIV-VL was associ-
ated with NHL only. This suggests that NHL development is related to both CD4 cell depletion and added immune dysfunc-
tion derived from ongoing HIV replication. This latter factor was not associated with HL risk.
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Use of combination antiretroviral treatment (cART) in people
living with HIV (PLWH) has led to a decline in the incidence of
non-Hodgkin lymphoma (NHL; with the exception of Burkitt
lymphoma [BL]) but not Hodgkin lymphoma (HL) (1–10). Recent
estimates indicate that the incidence rates of NHL and HL
remain elevated in PLWH compared with the general popula-
tion, with NHL incidence estimated to be around 10-fold higher
(11–13) and HL incidence estimated to be around 11-fold higher
(9,12).
In PLWH, the pathogenesis of NHL and HL is thought to be
driven by a combination of latent infection with Epstein-Barr vi-
rus (EBV) and HIV-associated immune suppression and dys-
function (14–16). The interaction between HIV infection,
immune suppression and dysfunction, and EBV co-infection is
thought to differ between NHL and HL, as well as between NHL
subtypes (17). For example, approximately half of BL cases occur
at relatively preserved CD4 cell counts and are not EBV related
(18). Primary brain lymphomas (PBCNSL) often occur at very low
CD4 levels; however, a lack EBV-specific CD4 T-cell function has
been shown in PLWH people prior to PBCNSL development, irre-
spective of absolute CD4 cell counts (19). Almost all HL cases are
EBV related in PLWH, and although HL is associated with low
CD4 cell counts (8,18,20,21), it is not as strong as for PBCNSL or
diffuse large B-cell lymphomas.
Several prior studies have suggested that the risk factors and
strengths of associations differ for NHL and HL in the context of
PLWH (22–29). For example, older age has been linked to NHL;
however, several studies have reported no association between
HL incidence and age in PLWH (20,30–34). Many studies have
identified an association between lower current CD4 cell count
and both NHL and HL incidence (5,20,31,35–39). However, both
current and cumulative HIV-VL have been linked with NHL inci-
dence, independent of CD4 (34,40), an association not usually
reported for HL (37). The START study demonstrated that imme-
diate cART statistically significantly reduced the risk of
infection-related cancers, independent of CD4 and HIV-VL, sug-
gesting that HIV-associated cancer risk is mediated through
other mechanisms such as immune activation and reduced im-
mune surveillance, above and beyond the depletion of CD4 cell
counts (41).
Although there are many studies investigating incidence of
NHL and HL since the introduction of cART and associated risk
factors, to our knowledge no studies have directly compared the
risk factors. Therefore, we aimed to identify independent risk
factors of NHL and HL and to identify factors that differentially
affect NHL and HL risk in order to develop an understanding of
different mechanistic pathways, which may then suggest differ-
ent preventive approaches for reducing NHL and HL risk.
Methods
The Data Collection on Adverse Events of Anti-HIV
Drugs Study
The Data Collection on Adverse events of Anti-HIV Drugs Study
(D:A:D) is a prospective cohort collaboration established in 1999;
the data set includes more than 49 000 HIV-1-positive people in
Europe, the United States, and Australia. The D:A:D Study has
been described in detail previously (42). Data for routine clinical
care, including demographic factors, HIV treatment, laboratory
values, and AIDS-defining events (including NHL [43]) are col-
lected at enrollment and annually thereafter. Non-AIDS-
defining cancers, such as HL, have been routinely collected and
validated since January 1, 2004. Detailed information on all non-
AIDS-defining cancers is collected via designated case report
forms, including date of diagnosis, type/location of cancer,
stage, and histology/cytology report or other applied diagnostic
methods, such as imaging and biochemical assays, and this in-
formation is supplemented by submitted source documentation
supporting the way of diagnosis. NHL is further characterized
by histological type (BL, diffuse large B-cell lymphoma [DLBCL],
PBCNSL, and other or unknown). All events are centrally vali-
dated at the D:A:D coordinating center by a medical doctor, with
a proportion of complicated cases selected to be reviewed by an
external oncologist. Events are regularly monitored for accu-
racy, with random monitoring at participating sites to ensure
complete case ascertainment. All participating cohorts followed
local national guidelines or regulations regarding patient con-
sent and ethical review, and written consent from individual
participants was obtained when this was required according to
the local and/or national study requirements. In particular, of
the countries represented by the participating cohorts, only
Switzerland and Australia require specific ethical approval for
D:A:D in addition to that required for their national cohorts
(Swiss HIV Cohort Study and the Australian HIV Observational
Database), both of which have obtained this approval.
Hodgkin and Non-Hodgkin Lymphomas
We investigated the association between immunological and vi-
rological factors and two main outcomes: 1) first diagnosis of
NHL and 2) first diagnosis of HL during follow-up. Baseline was
defined as the latest of date of study entry, first reported CD4
cell count, or January 1, 2004, and people were followed from
baseline until the earliest of NHL or HL diagnosis, last visit plus
six months, death, or February 1, 2015.
Statistical Analysis
We investigated the associations between nadir and current
CD4 cell count, and current and area under the curve (AUC) of
HIV-VL and each outcome. The AUC of HIV-VL refers to the area
under each individual’s viral load curve (44), which was calcu-
lated using all HIV-VL measures since entry into D:A:D.
Formally, it can be interpreted as the total number of copies/mL
of HIV-RNA accumulated over time. For example, an AUC of
HIV-VL of 10 000 copies/Ml per year is equal to having a HIV-VL
of 10 000 copies/mL for one year or an HIV-VL of 1000 copies/mL
for 10 years. Due to the high correlation between nadir and cur-
rent CD4, only one measure was included in the analysis
according to the lowest Akaike information criterion (AIC) for
both NHL and HL. Current and AUC of HIV-VL were not strongly
correlated, and therefore both were included in the same
model.
Incidence rates of NHL and HL were calculated by calendar
year of follow-up. Separate Cox regression models were used to
identify factors associated with NHL and HL, focusing on cur-
rent and nadir CD4, and current and AUC of HIV-VL. Models
were adjusted for baseline factors (sex, HIV transmission mode,
ethnicity, calendar year of baseline) and current factors (age,
body mass index [BMI], smoking status, hepatitis B and C coin-
fection, prior AIDS-defining cancer [excluding NHL], AIDS-
defining diagnosis [excluding cancer], hypertension [diastolic
blood pressure >90 mmHg, systolic blood pressure >140 mmHg,
receiving antihypertensive medication or ACE inhibitors], car-
diovascular disease, diabetes [as validated event or use of
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antidiabetic medication], and cumulative time on cART [defined
as being on one or more protease inhibitors or non-nucleoside
reverse transcriptase inhibitor). Immunological and virological
risk factors for NHL subtypes were also investigated in those
with NHL subtype reported (33.6%).
The Wei, Lin, and Weissfeld method, based on marginal Cox
models (45) was used to identify factors that differently affected
NHL and HL risk. The models were used to jointly calculate and
compare adjusted hazard ratios (aHRs) for NHL and HL for all
current and historical measures of HIV-VL and CD4 cell count
(separately), adjusting for variables listed previously. In order to
fit a more parsimonious model, variables not associated with ei-
ther NHL or HL incidences were assumed to have a similar asso-
ciation for both NHL and HL. The remaining variables were
allowed to vary according to outcome. The marginal Cox models
differed to those used to identify independent risk factors with
minor differences in adjustments (fixed and outcome-specific
variables) that give slightly different estimates. The ratio of the
adjusted HRs (RHR) was used to identify factors with different
risk profiles for NHL and HL, which we have termed “differential
factors.” Variables for which the 95% confidence interval for the
RHR cross 1 indicate a similar association between the risk fac-
tor and both HL and NHL.
All statistical tests were two-sided. A P value of less than .05
was considered statistically significant. All statistical analyses
were performed using SAS 9.4 (Statistical Analysis Software,
Cary, NC). All bivariate associations were tested using chi-
square tests for categorical variables and Kruskal-Wallis tests
for numerical variables.
Results
Study Population
There were 41 420 people included in the analysis contributing
337 020 PYFU with a median follow-up of 9.2 years per person
(interquartile range [IQR] ¼ 6.3–11.1 years per person). A total of
392 people developed NHL (incidence rate [IR] ¼ 1.17/1000 PYFU,
95% confidence interval [CI] ¼ 1.06 to 1.30), and 149 developed
HL (IR ¼ 0.44/1000 PYFU, 95% CI ¼ 0.38 to 0.52) during follow-up.
Baseline Characteristics
Baseline characteristics of the study population, as well as those
who developed NHL or HL during follow-up, are shown in
Table 1. Overall, 17.4% were age 50 years or older at baseline,
72.9% were male, and 43.8% acquired their HIV through sex be-
tween men; 49.9% were of white ethnicity, and 40.9% had un-
known ethnicity. Just over half were on cART (51.8%) at
baseline, with a median cART duration of 1.1 years (IQR ¼ 0.0–
4.9 years). The median CD4 cell count was 431 cells/mm3 (IQR ¼
280–620 cells/mm3), and the median HIV-VL was 260 copies/mL
(IQR  50–20 400 copies/mL).
Crude Incidence Rates Over Time
The crude incidence rates of NHL and HL by calendar year are
shown in Figure 1. The crude incidence of NHL declined by
13.3% per year (95% CI¼ 10.3 to 16.2%), from an incidence rate
of 1.96 (95% CI¼ 1.48 to 2.58) events/1000 PYFU in 2004 to 0.32
(95% CI¼ 0.17 to 0.62) in 2014/15. In 2014/15, the incidence of
NHL was similar to HL (HL incidence ¼ 0.36, 95% CI¼ 0.19 to
0.66); however, HL incidence was stable over time (change per
year ¼ –2.7%, 95% CI¼ –7.7% to 2.6%).
Independent Risk Factors for NHL and HL
Current and nadir CD4 cell counts were considered for inclusion
in the main analysis. Both associated with NHL in adjusted
analyses, whereas only current CD4 was associated with HL.
However, current CD4 was the strongest immune marker for
both NHL and HL, so it was the only immunological marker in-
cluded in multivariable models (provided the best statistical fit,
measured as by the AIC).
Independent risk factors of NHL and HL from a multivariable
model are shown in Table 2. For example, a higher rate of NHL
was strongly associated with lower current CD4 cell count cate-
gory (CD4 <100 vs >599 cells/mm3: aHR ¼ 8.08, 95% CI¼ 5.63 to
11.61), higher current HIV-VL (HIV-VL >1000 vs <50 copies/mL:
aHR¼ 1.97, 95% CI¼ 1.50 to 2.59), and higher AUC of HIV-VL
(highest vs lowest quintile: aHR¼ 2.91, 95% CI¼ 1.92 to 4.41).
Higher rates of NHL were also observed in older people and
males. A higher rate of HL was also associated with lower cur-
rent CD4 cell count category; however, no association was
found for current or AUC of HIV-VL. Current smokers had a
1.97-fold (95% CI¼ 1.23 to 3.16) higher rate of HL compared with
nonsmokers. No association was found for HCV or HBV status
with either NHL or HL. Rates of both NHL and HL reduced with
longer time on cART.
Differences in Risk Factors for NHL and HL
Factors that were associated with either NHL or HL in Table 2
were jointly modeled to identify factors that were differently as-
sociated with NHL and HL (differential factors). Current HIV-VL
was a differential factor, as demonstrated by the increase in ra-
tio of the aHRs with higher HIV-VL category (Figure 2). For
example, the RHRs were 2.52 (95% CI¼ 1.32 to 4.81) and 4.57
(95% CI¼ 2.20 to 9.50) in those with current HIV-VL 50–1000
copies/mL and more than 1000 copies/mL, relative to less than
50 copies/mL, respectively, indicating a progressively stronger
association with NHL than for HL with higher current HIV-VL. A
similar result was found for the AUC of HIV-VL, which was also
a differential factor. Current CD4 was not a differential factor as
the 95% confidence interval of the ratio of the aHRs for each
CD4 cell count category relative to CD4 200–299 cells/mm3 con-
tained 1, indicating no evidence that lower CD4 cell count was
differently associated with NHL and HL. Age was a differential
risk factor as the ratio of the aHRs of people older than age 60
years relative to those age 30 to 39 years was 3.06 (95% CI¼ 1.43
to 6.55), indicating a relatively higher increase in rates of NHL
than HL for people in this older age group. Finally, smoking sta-
tus was a differential factor, as the ratio of the aHRs for current
smokers relative to never smokers was 0.49 (95% CI¼ 0.28 to
0.83), indicating a statistically significantly higher relative in-
crease in risk for HL in this group. No other factors investigated
were differential factors.
NHL Subtypes
Of the 392 NHL, 42 were BL (10.7%), 25 were PBCNSL (6.4%), 65
were DLBCL (16.6%), and 260 were unknown (66.3%) (Table 3).
People with known and unknown NHL subtype had similar
characteristics at diagnosis. Slightly more people with known
subtype reported being on protease inhibitors (known subtype
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Table 1. Baseline characteristics of D:A:D participants included in the analysis
All persons (n¼ 41 420) Persons who developed NHL (n¼392) Persons who developed HL (n¼149)
Factors No. (%) No. (%) No. (%)
Age, y
<30 5922 (14.3) 22 (5.6) 16 (10.7)
30–39 14 833 (35.8) 118 (30.1) 44 (29.5)
40–49 13 449 (32.5) 142 (36.2) 56 (37.6)
50–59 5170 (12.5) 71 (18.1) 23 (15.4)
60 2046 (4.9) 39 (9.9) 10 (6.7)
Sex
Male 30 214 (72.9) 337 (86.0) 126 (84.6)
Female 11 206 (27.1) 55 (14.0) 23 (15.4)
HIV-transmission mode
Homosexual 18 124 (43.8) 200 (51.0) 87 (58.4)
IDU 5926 (14.3) 53 (13.5) 15 (10.1)
Heterosexual 14 800 (35.7) 106 (27.0) 39 (26.2)
Other/unknown 2570 (6.2) 33 (8.4) 8 (5.4)
Race
White 20 658 (49.9) 181 (46.2) 70 (47.0)
Black 2963 (7.2) 10 (2.6) 6 (4.0)
Other 840 (2.0) 7 (1.8) 3 (2.0)
Unknown 16 959 (40.9) 194 (49.5) 70 (47.0)
Smoking status
Current 16 859 (40.7) 155 (39.5) 70 (47.0)
Ex 7332 (17.7) 65 (16.6) 31 (20.8)
Never 11 364 (27.4) 98 (25.0) 28 (18.8)
Unknown 5865 (14.2) 74 (18.9) 20 (13.4)
BMI group, kg/m2
<18 1377 (3.3) 13 (3.3) 4 (2.7)
18–26 27 709 (66.9) 255 (65.1) 102 (68.5)
27–30 5360 (12.9) 59 (15.1) 15 (10.1)
>30 1833 (4.4) 16 (4.1) 10 (6.7)
Unknown 5141 (12.4) 49 (12.5) 18 (12.1)
Previous AIDS diagnosis
(excluding ADC)
8801 (21.2) 85 (21.7) 31 (20.8)
Previous ADC diagnosis 1419 (3.4) 26 (6.6) 8 (5.4)
On cART 21 436 (51.8) 161 (41.1) 70 (47.0)
HBV
Negative 29 355 (70.9) 271 (69.1) 119 (79.9)
Positive/prior 7831 (18.9) 86 (21.9) 19 (12.8)
Unknown 4234 (10.2) 35 (8.9) 11 (7.4)
HCV
Negative 28 168 (68.0) 261 (66.6) 117 (78.5)
Positive 7947 (19.2) 76 (19.4) 19 (12.8)
Unknown 5305 (12.8) 55 (14.0) 13 (8.7)
Prior CVD 857 (2.1) 5 (1.3) 6 (4.0)
Diabetes* 1055 (2.5) 12 (3.1) 2 (1.3)
Hypertension† 6121 (14.8) 68 (17.3) 30 (20.1)
Baseline year
2004–2005 29 715 (71.7) 290 (74.0) 99 (66.4)
2006–2007 6334 (15.3) 65 (16.6) 29 (19.5)
2008–2009 5327 (12.9) 35 (8.9) 21 (14.1)
2010–2011 29 (0.1) 1 (0.3) 0 (0.0)
2012–2015 15 (0.0) 1 (0.3) 0 (0.0)
HIV-VL 500 copies/mL 21 546 (52.0) 113 (28.8) 65 (43.6)
Age, y 41 420 40 (34,47) 392 43 (38,51) 149 42 (35,49)
CD4 count, cells/mm3 41 420 431 (280,620) 392 342 (189,534) 149 409 (276,575)
Nadir CD4 count, cells/mm3 41 420 248 (116,403) 392 197 (77,368) 149 259 (130,409)
Time CD4 <200 cells/mm3, y 37 962 0.0 (0.0,0.4) 353 0.0 (0.0,0.6) 137 0.0 (0.0,0.2)
HIV-VL, cps/mL 39 883 260 (<50,20 400) 378 13419 (80,90951) 146 2615 (<50,34000)
Log10 AUC HIV-VL, copies/mL per y 36 840 4.2 (3.0,4.9) 345 4.5 (3.3,5.2) 135 4.3 (2.4,5.0)
*Diabetes defined as a validated event reported on a case-report form or use of antidiabetic medication. ADC ¼ AIDS-defining cancer; AUC ¼ area under the curve; BMI
¼ body mass index; cART ¼ combination antiretroviral treatment; CVD ¼ cardiovascular disease; HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus; HIV-VL ¼ HIV viral
load; HL ¼ Hodgkin lymphoma; IDU ¼ Injecting drug use; NHL ¼ non-Hodgkin lymphoma.
†Hypertension defined as diastolic blood pressure >90 mmHg or systolic blood pressure >140 mmHg or receiving antihypertensive medication.
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¼ 46.2% vs unknown subtype ¼ 38.6%, P ¼ .05), and slightly
fewer people had a previous cancer diagnosis (3.1% vs 10.6%, P
¼ .02; data not shown). Associations between immunological
and virological risk factors for each subtype (in those with a
subtype recorded) are shown in Table 3. For example, lower risk
of PBCNSL was associated with higher current and nadir CD4
cell count (aHR for twofold higher ¼ 0.59, 95% CI¼ 0.51 to 0.70;
aHR for twofold higher ¼ 0.68, 95% CI¼ 0.58 to 0.80, respec-
tively) and lower AUC of HIV-VL (aHR for 10-fold higher ¼ 2.21,
95% CI¼ 1.22 to 4.00), but not current HIV-VL. Lower DLBCL NHL
risk was associated with higher current and nadir CD4 and
lower current and AUC of HIV-VL. Lower BL risk was associated
with higher current and AUC of HIV-VL but not immunological
markers. Nadir CD4 cell count was not associated with PBCNSL,
DLBCL lymphoma, or BL after additional adjustment for current
CD4 cell count.
Discussion
This study is the first to attempt to identify differences in the
underlying pathology of NHL and HL in PLWH by directly com-
paring the immunological and virological risk factors for each
and identifying differences. Higher current and cumulative ex-
posure to HIV-VL were stronger risk factors for NHL than HL.
Although current CD4 was a strong predictor of both, there was
no evidence of a different association between with NHL and
HL. In this study, the crude incidence of NHL declined steadily
over time while HL incidence remained stable. The trends over
time are not surprising and have been reported before (1–10);
however, our study is one of the first to show that incidence of
NHL and HL is similar in PLWH in recent years. This highlights a
shift away from the cancers with a strong link with immune de-
ficiency and the need for a better understanding of how
generalized immune dysfunction (beyond low CD4 cell counts)
can facilitate lymphoma development.
The risk of NHL and HL differed according to current and ac-
cumulated HIV-VL, but not current CD4 cell count. Our results
indicate a similar pathological requirement of immunodefi-
ciency for both NHL and HL development; however, an impor-
tant distinction is the involvement of HIV-VL in NHL but not HL
development. This indicates that HIV infection may contribute
to lymphomagenesis of NHL through additional immune dys-
function not captured by supressed CD4 (46), possibly though
reduced immune surveillance for proteins expressed by cells
infected with latent EBV, immune activation, and/or CD8
dysfunction, leading to depleted response from EBV-specific
CD8 cytotoxic cells (14–16,19,47,48). Some studies have found
that levels of circulating free light chains have predictive value
of NHL in PLWH, which supports the involvement of immune
activation (49,50). In addition, the ratio and percentage of CD8
cells have been shown to be predictive of HL (30) and may also
be predictive of EBV-associated NHL (19,51). Alternatively, HIV
may play a more direct role in lymphomagenesis (46,52), with
HIV-derived p17 secreted within lymphoid tissues possibly pro-
moting lymphoma development by inducing changes to the mi-
croenvironment (52). Furthermore, the CD4-independent effect
of HIV-VL was statistically significant and consistent across the
known subtypes studied. This was surprising in the case of BL,
which has little association with CD4 (53).
Smoking status had a different association with HL and NHL,
where risk of HL was elevated in current smokers. Research in
the general population has indicated that smoking may play an
etiological role in HL, particularly EBV positive (54,55). Almost
all HL in PLWH is EBV related; therefore, smoking presents as
one of the few modifiable risk factors for this cancer, which
emphasizes the importance of smoking cessation strategies in
PLWH. Age had a different association with NHL and HL, where
people older than age 50 years had a higher relative increase in
the rate of NHL than for HL, which is consistent with previous
studies (14,20,30,32,33,56). This may reflect increases in im-
mune activation and inflammation associated with aging and
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Hodgkin lymphoma; PYFU ¼ person-years of follow-up.
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Table 2. Adjusted hazard ratios and 95% confidence intervals for factors associated with non-Hodgkin lymphoma and Hodgkin lymphoma
NHL HL
Factors aHR* (95% CI) P† aHR* (95% CI) P†
Current CD4 cell count, cells/mm3‡
<100 8.08 (5.63 to 11.61) <.001 4.58 (2.22 to 9.45) <.001
100–199 3.67 (2.49 to 5.39) <.001 6.36 (3.62 to 11.20) <.001
200–299 2.96 (2.12 to 4.13) <.001 3.37 (1.99 to 5.69) <.001
300–399 2.43 (1.78 to 3.33) <.001 1.72 (0.99 to 2.97) .05
400–499 1.62 (1.15 to 2.29) .006 2.59 (1.64 to 4.08) <.001
500 Reference Reference
Current HIV-VL‡
50 Reference Reference
51–1000 1.35 (1.00 to 1.83) .05 1.08 (0.69 to 1.69) .72
>1000 1.97 (1.50 to 2.59) <.001 0.67 (0.39 to 1.17) .16
Unknown 0.65 (0.15 to 2.81) .56 3.73 (0.22 to 62.35) .36
AUC of HIV-VL, quintiles‡
1, lowest Reference Reference
2 1.10 (0.69 to 1.76) .69 0.65 (0.37 to 1.12) .12
3 1.47 (0.94 to 2.30) .09 0.79 (0.47 to 1.34) .38
4 1.81 (1.17 to 2.80) .007 0.65 (0.38 to 1.14) .13
5, highest 2.91 (1.92 to 4.41) <.001 1.01 (0.61 to 1.68) .97
Unknown 1.63 (0.93 to 2.85) .09 0.14 (0.02 to 1.04) .06
Age, y‡
<30 0.49 (0.27 to 0.89) .02 0.90 (0.41 to 1.95) .78
30–39 Reference Reference
40–49 1.53 (1.16 to 2.01) .003 1.25 (0.81 to 1.93) .32
50–59 2.02 (1.47 to 2.78) <.001 1.37 (0.82 to 2.28) .22
60 3.15 (2.17 to 4.58) <.001 1.06 (0.53 to 2.15) .87
Female sex 0.55 (0.40 to 0.76) <.001 0.73 (0.43 to 1.25) .25
Race
White Reference Reference
Other 0.65 (0.39 to 1.10) .11 0.98 (0.47 to 2.04) .95
Unknown 0.99 (0.80 to 1.24) .95 0.95 (0.66 to 1.35) .76
HIV transmission mode
Homosexual Reference Reference
IDU 0.91 (0.59 to 1.40) .68 0.72 (0.32 to 1.59) .41
Heterosexual 0.91 (0.70 to 1.20) .52 0.67 (0.42 to 1.06) .08
Unknown 1.35 (0.92 to 1.98) .13 0.78 (0.37 to 1.66) .53
Smoking‡
Current 0.91 (0.69 to 1.19) .48 1.97 (1.23 to 3.16) .01
Ex 0.89 (0.66 to 1.21) .46 1.54 (0.92 to 2.58) .10
Never Reference Reference
Unknown 1.35 (0.96 to 1.89) .08 1.25 (0.63 to 2.47) .52
on cART‡ , y
Never 1.41 (0.95 to 2.10) .09 1.25 (0.60 to 2.60) .56
0.1–2 1.71 (1.23 to 2.38) .001 1.63 (0.97 to 2.74) .06
2.1–4 Reference Reference
>4 0.66 (0.47 to 0.91) .01 0.75 (0.45 to 1.23) .26
Previous ADM diagnosis‡ 1.49 (1.02 to 2.19) .04 1.10 (0.55 to 2.18) .79
Previous AIDS diagnosis (excl. ADM)‡ 1.01 (0.79 to 1.28) .97 0.99 (0.67 to 1.46) .96
HBV‡
Positive/prior 1.10 (0.85 to 1.41) .48 0.75 (0.47 to 1.20) .23
Negative Reference Reference
Unknown 0.97 (0.62 to 1.53) .91 0.94 (0.40 to 2.25) .90
HCV‡
Positive/prior 1.13 (0.81 to 1.59) .46 0.66 (0.35 to 1.24) .19
Negative Reference Reference
Unknown 1.20 (0.78 to 1.84) .42 0.33 (0.10 to 1.10) .07
Baseline year
2004 Reference Reference
2005 1.54 (1.1 to 2.16) .01 1.04 (0.53 to 2.03) .92
2006 1.2 (0.85 to 1.69) .30 1.37 (0.78 to 2.41) .28
(continued)
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Table 2. (continued)
NHL HL
Factors aHR* (95% CI) P† aHR* (95% CI) P†
2007 1.01 (0.65 to 1.58) .96 1.85 (1.02 to 3.38) .04
2008/9 0.92 (0.63 to 1.33) .64 1.69 (1.01 to 2.83) .05
*Models were adjusted for all other covariates in the table and further adjusted for body mass index (BMI), prior cardiovascular disease (CVD) diagnosis, hypertension,
diabetes. ADC ¼ AIDS-defining cancer; aHR ¼ adjusted hazard ratio; AUC ¼ area under the curve; cART ¼ combination antiretroviral treatment; CI ¼ confidence inter-
val; HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus; HIV-VL ¼ HIV viral load; HL ¼ Hodgkin lymphoma; IDU ¼ Injecting drug use; NHL ¼ non-Hodgkin lymphoma.
†P value of the Wald chi-square statistic with respect to a chi-square distribution with one degree of freedom. All statistical tests of significance were two-sided.
‡Time updated variables.
Figure 2. Adjusted ratio of the hazard ratios of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) for each considered risk factor. P value of the Wald chi-
square statistic with respect to a chi-square distribution with one degree of freedom. All statistical tests of significance were two-sided. Models were adjusted for age,
sex, ethnicity, mode of HIV acquisition, smoking status, body mass index, baseline year, cumulative time on combination antiretroviral treatment, hepatitis C virus
and hepatitis B virus status, prior AIDS-defining cancer (ADC), prior AIDS events (excluding ADC), prior cardiovascular disease diagnosis, hypertension, diabetes, cur-
rent CD4, current HIV viral load, area under the curve of HIV-viral load. Risk factors for which the 95% confidence interval for the ratio of the hazard ratios of NHL to HL
does not cross 1 (and a corresponding P value < .05) indicate that there is evidence of a different association of the risk factor with HL and NHL. AUC ¼ area under the
curve; cART ¼ combined antiretroviral therapy; CI ¼ confidence interval; HIV-VL ¼ HIV viral load; HL ¼ Hodgkin lymphoma; HR ¼ hazard ratios; NHL ¼ non-Hodgkin
lymphoma; RHR ¼ ratio of the hazard ratios.
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further supports the hypothesis that immune dysfunction be-
yond low CD4 is involved in the pathology (57). The lack of asso-
ciation between either HCV or HBV status and NHL or HL is in
contrast to results from the COHERE study, which found a sta-
tistically significant association between both HCV and HBV
and NHL risk in treated patients (58), and two meta analyses
(59,60), although other studies have failed to show a convincing
association (20,61,62).
This study has many advantages. The D:A:D study contains
follow up on more than 40 000 people and allows for the analy-
sis of a relatively large number of prospectively collected and
validated NHL and HL events. Furthermore, the D:A:D data con-
tain highly detailed demographic, HIV, and health-related fac-
tors collected over a long follow-up period. However, the
limitations need to be considered. There are several known risk
factors for NHL and HL that are not collected in D:A:D, for exam-
ple, autoimmune disorders and family history. Furthermore,
NHL subtype is only reported by a subset of cohorts in D:A:D,
and as a result it was missing on 66% of people; however, the
characteristics of those with and without subtype information
were similar. D:A:D does not collect additional markers of im-
mune suppression or dysfunction, or EBV viral load. And finally,
this is an observational study, and it is possible that confound-
ing due to unmeasured or unknown factors remains and the
causality of the associations presented here cannot be deter-
mined. It should also be kept in mind that NHL is treated as a
single entity the main analysis; however, there is considerable
heterogeneity in etiology between NHL subtypes (63). Several
studies from the COHERE collaboration have been referred to;
however, these studies are in naı¨ve patients, of which the pro-
portion in D:A:D is very low, resulting in minimal overlap be-
tween the two studies.
In conclusion, whereas CD4 depletion similarly increased
risk of both types of lymphomas, current and accumulated HIV-
VL was more predictive of NHL than HL. This suggests that NHL
development is related to both CD4 cell depletion and added im-
mune dysfunction derived from ongoing HIV replication. This
latter factor was not associated with HL risk. These findings
stress the importance of early HIV diagnosis and treatment, and
of ensuring sustained viral suppression.
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Table 3. Adjusted hazard ratios and 95% confidence intervals for factors associated with NHL subtypes
Factor
PBCNSL (n¼ 25) DLBCL (n¼ 65) BL (n¼ 42)
aHR* (95% CI) P† aHR* (95% CI) P† aHR* (95% CI) P†
Log2 current CD4‡ 0.59 (0.51 to 0.70) .001 0.75 (0.67 to 0.85) <.001 0.88 (0.74 to 1.05) .15
Log2 nadir CD4‡ 0.68 (0.58 to 0.80) .001 0.87 (0.77 to 0.98) .02 0.97 (0.82 to 1.14) .68
Log10 current HIV-VL§ 1.11 (0.80 to 1.54) .54 1.32 (1.08 to 1.61) .006 1.38 (1.08 to 1.76) .01
Log10 of AUC of HIV-VL§ 2.21 (1.22 to 4.00) .009 1.60 (1.16 to 2.21) .004 2.14 (1.35 to 3.38) .001
*Models were adjusted age, sex, mode of HIV acquisition, race, current smoking status, cumulative time on combination antiretroviral treatment. AUC ¼ area under
the curve; BL ¼ Burkitt lymphoma; DLBCL ¼ diffuse large B cell lymphoma; HIV-VL ¼ HIV viral load; PBCNSL ¼ primary brain and central nervous system lymphoma.
†P value of the Wald chi-square statistic with respect to a chi-square distribution with one degree of freedom. All statistical tests of significance were two-sided.
‡Models were additionally adjusted for log10 current HIV-VL and log10 of area under the curve of HIV-VL, in addition to age, sex, mode of HIV acquisition, race, current
smoking status, cumulative time on cART.
§Models were additionally adjusted for log2 current CD4, in addition to age, sex, mode of HIV acquisition, race, current smoking status, cumulative time on cART.
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